5.695
price down icon6.02%   -0.365
 
loading
Apollomics Inc stock is traded at $5.695, with a volume of 3,745. It is down -6.02% in the last 24 hours and up +6.95% over the past month. Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
See More
Previous Close:
$6.06
Open:
$5.96
24h Volume:
3,745
Relative Volume:
0.15
Market Cap:
$7.44M
Revenue:
-
Net Income/Loss:
$-57.11M
P/E Ratio:
-0.3797
EPS:
-15
Net Cash Flow:
$-34.82M
1W Performance:
-6.22%
1M Performance:
+6.95%
6M Performance:
-41.59%
1Y Performance:
-70.84%
1-Day Range:
Value
$5.50
$6.00
1-Week Range:
Value
$5.50
$6.7509
52-Week Range:
Value
$4.4701
$35.98

Apollomics Inc Stock (APLM) Company Profile

Name
Name
Apollomics Inc
Name
Phone
-
Name
Address
-
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
APLM's Discussions on Twitter

Compare APLM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLM
Apollomics Inc
5.695 7.44M 0 -57.11M -34.82M -15.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Apollomics Inc Stock (APLM) Latest News

pulisher
Jun 12, 2025

New Age Metals (OTCMKTS:NMTLF) Trading 1.2% Higher – Here’s Why - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 87.9% - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Orca Energy Group (OTCMKTS:ORXGF) Trading 1.4% Higher – What’s Next? - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

(APLM) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 10, 2025
pulisher
May 31, 2025

Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World

May 31, 2025
pulisher
May 29, 2025

How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com

May 29, 2025
pulisher
May 23, 2025

Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus

May 23, 2025
pulisher
May 08, 2025

(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 08, 2025
pulisher
Apr 16, 2025

Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada

Apr 15, 2025
pulisher
Apr 06, 2025

(APLM) Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 04, 2025

APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times

Apr 03, 2025
pulisher
Apr 03, 2025

Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia

Apr 02, 2025
pulisher
Apr 01, 2025

Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo

Apr 01, 2025
pulisher
Apr 01, 2025

Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com

Mar 28, 2025
pulisher
Mar 24, 2025

Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail

Mar 24, 2025
pulisher
Mar 17, 2025

Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World

Mar 17, 2025
pulisher
Mar 07, 2025

These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail

Mar 07, 2025
pulisher
Mar 06, 2025

(APLM) Trading Advice - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 02, 2025

Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 25, 2025

GlycoMimetics ends key agreement; board members, executives depart - Investing.com

Feb 25, 2025
pulisher
Feb 12, 2025

APLM stock touches 52-week low at $6.38 amid market challenges - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 01, 2025

Objective long/short (APLM) Report - Stock Traders Daily

Feb 01, 2025
pulisher
Jan 29, 2025

Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World

Jan 29, 2025
pulisher
Dec 20, 2024

Apollomics phase 3 trial in China shows no benefit - Investing.com India

Dec 20, 2024
pulisher
Dec 20, 2024

Biotech fails trials for its leukemia drug - Silicon Valley Business Journal

Dec 20, 2024
pulisher
Dec 20, 2024

Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch

Dec 20, 2024
pulisher
Dec 20, 2024

Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire

Dec 20, 2024
pulisher
Dec 20, 2024

Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan

Dec 20, 2024
pulisher
Dec 20, 2024

Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech

Dec 20, 2024
pulisher
Dec 11, 2024

APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia

Dec 11, 2024
pulisher
Dec 10, 2024

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire

Dec 10, 2024
pulisher
Nov 30, 2024

When the Price of (APLM) Talks, People Listen - Stock Traders Daily

Nov 30, 2024
pulisher
Nov 26, 2024

APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com

Nov 26, 2024

Apollomics Inc Stock (APLM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Cap:     |  Volume (24h):